Register Login

ACTUATE THERAPEUTICS, INC. (ACTU)

SymbolACTU
NameACTUATE THERAPEUTICS, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address1751 RIVER RUN,SUITE 400, FORT WORTH, Texas, 76107, United States
Telephone+1 817 - 887-8455
Fax—
Email—
Websitehttps://www.actuatetherapeutics.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK—
Description

Actuate Therapeutics is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). We are developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B. We believe that the blockade of GSK-3B signaling ultimately results in the death of the cancer cells and the regulation of anti-tumor immunity. We have exclusively licensed a portfolio of GSK-3 inhibitors developed in a collaboration between the University of Illinois-Chicago (UIC) and Northwestern University (NU).

Additional info from NASDAQ:
Actuate Therapeutics is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). We are developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B. We believe that the blockade of GSK-3B signaling ultimately results in the death of the cancer cells and the regulation of anti-tumor immunity. We have exclusively licensed a portfolio of GSK-3 inhibitors developed in a collaboration between the University of Illinois-Chicago (UIC) and Northwestern University (NU).

2026-04-22 16:25

New Form SCHEDULE 13G/A - ACTUATE THERAPEUTICS, INC. <b>Filed:</b> 2026-04-22 <b>AccNo:</b> 0002060757-26-000023 <b>Size:</b> 22 KB

Read more
2026-04-14 12:45

Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Read more
2026-04-09 17:04

New Form ARS - ACTUATE THERAPEUTICS, INC. <b>Filed:</b> 2026-04-09 <b>AccNo:</b> 0001683168-26-002780 <b>Size:</b> 2 MB

Read more
2026-04-06 17:07

New Form DEFA14A - ACTUATE THERAPEUTICS, INC. <b>Filed:</b> 2026-04-06 <b>AccNo:</b> 0001683168-26-002692 <b>Size:</b> 247 KB

Read more
2026-04-06 17:06

New Form DEF 14A - ACTUATE THERAPEUTICS, INC. <b>Filed:</b> 2026-04-06 <b>AccNo:</b> 0001683168-26-002691 <b>Size:</b> 1 MB

Read more
2026-04-01 21:19

Director SCHMITT DANIEL M 🟢 acquired 237.0K shares (1 derivative) of ACTUATE THERAPEUTICS, INC. (ACTU) at $2.49 Transaction Date: Apr 01, 2026 | Filing ID: 002582

Read more
2026-04-01 21:19

Mazar Andrew Paul 🟢 acquired 105.0K shares (1 derivative) of ACTUATE THERAPEUTICS, INC. (ACTU) at $2.49 Transaction Date: Apr 01, 2026 | Filing ID: 002581

Read more
2026-04-01 21:19

LYTLE PAUL J 🟢 acquired 105.0K shares (1 derivative) of ACTUATE THERAPEUTICS, INC. (ACTU) at $2.49 Transaction Date: Apr 01, 2026 | Filing ID: 002580

Read more
2026-03-26 17:01

New Form 10-K - ACTUATE THERAPEUTICS, INC. <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0001683168-26-002257 <b>Size:</b> 9 MB

Read more
2026-03-09 12:45

Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors

Read more
Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT04832438 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland … Phase2 Salivary Gland Carcinoma Withdrawn 2030-12-18 2034-06-18 ClinicalTrials.gov
NCT06896188 9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With… Phase1 Pancreatic Adenocarcinoma Recruiting 2025-09-22 2028-12-31 ClinicalTrials.gov
NCT05077800 FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer Phase2 Pancreatic Adenocarcinoma Active_Not_Recruiting 2022-03-21 2026-07-31 ClinicalTrials.gov
NCT05116800 Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma Phase2 Soft Tissue Sarcoma Withdrawn 2022-03-01 2030-08-01 ClinicalTrials.gov
NCT05239182 9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Adva… Phase2 Pancreatic Adenocarcinoma Terminated 2022-01-26 2024-02-04 ClinicalTrials.gov
NCT05010629 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma Phase2 Salivary Gland Cancer Active_Not_Recruiting 2021-09-14 2027-04-12 ClinicalTrials.gov
NCT04906876 A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults… Phase2 Sarcoma Withdrawn 2021-09-01 2025-07-01 ClinicalTrials.gov
NCT04218071 Actuate 1901: 9-ING-41 in Myelofibrosis Phase2 Myelofibrosis Completed 2020-08-20 2024-01-18 ClinicalTrials.gov
NCT04239092 9-ING-41 in Pediatric Patients With Refractory Malignancies. Phase1 Refractory Cancer Terminated 2020-06-05 2025-07-07 ClinicalTrials.gov
NCT03678883 9-ING-41 in Patients With Advanced Cancers Phase2 Cancer Active_Not_Recruiting 2019-01-04 2026-06-01 ClinicalTrials.gov
Total clinical trials: 10
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
Chemotherapy DRUG Phase PHASE1 Pancreatic Adenocarcinoma RECRUITING NCT06896188
Abraxane DRUG Phase PHASE2 Pancreatic Adenocarcinoma TERMINATED NCT05239182
Retifanlimab DRUG Phase PHASE1 Pancreatic Adenocarcinoma RECRUITING NCT06896188
Losartan DRUG Phase PHASE2 Pancreatic Adenocarcinoma ACTIVE_NOT_RECRUITING NCT05077800
FOLFIRNINOX DRUG Phase PHASE2 Pancreatic Adenocarcinoma ACTIVE_NOT_RECRUITING NCT05077800
Docetaxel DRUG Phase PHASE2 Soft Tissue Sarcoma WITHDRAWN NCT05116800
Gemcitabine DRUG Phase PHASE2 Pancreatic Adenocarcinoma TERMINATED NCT05239182
Carboplatin DRUG Phase PHASE2 Salivary Gland Cancer ACTIVE_NOT_RECRUITING NCT05010629
Topotecan DRUG Phase PHASE1 Refractory Cancer TERMINATED NCT04239092
Cyclophosphamide DRUG Phase PHASE1 Refractory Cancer TERMINATED NCT04239092
Temozolomide DRUG Phase PHASE1 Refractory Cancer TERMINATED NCT04239092
Ruxolitinib DRUG Phase PHASE2 Myelofibrosis COMPLETED NCT04218071
Irinotecan DRUG Phase PHASE1 Refractory Cancer TERMINATED NCT04239092
Gemcitabine - 28 day cycle DRUG Phase PHASE2 Cancer ACTIVE_NOT_RECRUITING NCT03678883
Paclitaxel. DRUG Phase PHASE2 Cancer ACTIVE_NOT_RECRUITING NCT03678883
Nab paclitaxel. DRUG Phase PHASE2 Cancer ACTIVE_NOT_RECRUITING NCT03678883
Carboplatin. DRUG Phase PHASE2 Cancer ACTIVE_NOT_RECRUITING NCT03678883
Lomustine DRUG Phase PHASE2 Cancer ACTIVE_NOT_RECRUITING NCT03678883
Doxorubicin. DRUG Phase PHASE2 Cancer ACTIVE_NOT_RECRUITING NCT03678883
Gemcitabine - 21 day cycle DRUG Phase PHASE2 Cancer ACTIVE_NOT_RECRUITING NCT03678883
9-ING-41 DRUG Phase PHASE1 Pancreatic Adenocarcinoma RECRUITING NCT06896188
Total products: 21